⌘K
t
| Date | 5 Jun 2025 |
| Time | 17:30:00 |
| Category | Miscellaneous |
| ID | 6759L |
5 June 2025
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
Notice of Annual General Meeting - Clarification
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces, for the avoidance of doubt, that Resolution 3 in the Company's Notice of Annual General Meeting is for the re-election of Steen Andersen, the Company's Chief Executive Officer, as a Director of the Company. The reference to Steen "Anderson" is a typographical error. Existing Forms of proxy for use at the Annual General Meeting remain valid.
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
|
|
Mark Anwyl Duncan Vasey
|
Tel: 020 7469 0930 |
|
|
|
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.